Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA-Reference-Cited by-同舟云学术

Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA

Published:2015-09-14 Issue:4 Volume:55 Page:475-483
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Wagner Christian,Pan Yuzhuo,Hsu Vicky,Sinha Vikram,Zhao Ping

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40262-015-0330-y.pdf

Reference7 articles.

1. Zhang L, Zhang YD, Zhao P, Huang SM. Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009;11:300–6.

2. Wagner C, Pan Y, Hsu V, Grillo JA, Zhang L, Reynolds KS, et al. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration. Clin Pharmacokinet. 2015;54:117–27.

3. Vieira MD, Kim MJ, Apparaju S, Sinha V, Zineh I, Huang SM, et al. PBPK Model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways. Clin Pharmacol Ther. 2014;95:550–7.

4. Einolf HJ, Chen L, Fahmi OA, Gibson CR, Obach RS, Shebley M, et al. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharmacol Ther. 2014;95:179–88.

5. Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the twofold measure of prediction success for ratios: application for the assessment of drug–drug interactions. Drug Metab Dispos. 2011;39:170–3.

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions;Journal of Pharmacokinetics and Pharmacodynamics;2024-03-30

2. Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib;Pharmaceutics;2024-01-17

3. Docetaxel, Cyclophosphamide, and Epirubicin: Application of PBPK Modeling to Gain New Insights for Drug-Drug Interactions;2024-01-02

4. Regulatory Considerations in Metabolism‐ and Transport‐Based Drug Interactions;Oral Bioavailability and Drug Delivery;2023-10-10

5. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment;Scientific Reports;2023-09-25